Shares

7 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2022

Nov 07, 2023

SELL
$32.28 - $43.27 $0 - $0
0 Closed
0 $0
Q2 2022

Nov 07, 2023

SELL
$27.52 - $37.99 $81,982 - $113,172
-2,979 Closed
0 $0
Q1 2022

Nov 07, 2023

SELL
$30.71 - $45.71 $25,520 - $37,985
-831 Reduced 21.81%
2,979 $98.6 Million
Q2 2020

Nov 07, 2023

BUY
$25.95 - $43.15 $89,112 - $148,177
3,434 Added 913.3%
3,810 $158 Million
Q1 2020

Nov 07, 2023

BUY
$26.15 - $77.24 $9,832 - $29,042
376 New
376 $10.8 Million
Q3 2018

Nov 06, 2023

SELL
$138.11 - $169.04 $8,700 - $10,649
-63 Closed
0 $0
Q2 2018

Nov 06, 2023

BUY
$140.36 - $175.76 $8,842 - $11,072
63 New
63 $9.86 Million

Others Institutions Holding SAGE

About Sage Therapeutics, Inc.


  • Ticker SAGE
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,422,300
  • Market Cap $326M
  • Description
  • Sage Therapeutics, Inc., a biopharmaceutical company, develops and commercializes medicines to treat central nervous system disorders. Its lead product candidate is ZULRESSO, an intravenous formulation of brexanolone for the treatment of postpartum depression (PPD) in adults. The company's product pipeline also includes zuranolone, a neuroactive...
More about SAGE
Track This Portfolio

Track Sutton Wealth Advisors Inc. Portfolio

Follow Sutton Wealth Advisors Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Sutton Wealth Advisors Inc., based on Form 13F filings with the SEC.

News

Stay updated on Sutton Wealth Advisors Inc. with notifications on news.